Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2005-06-28
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S014800, C514S015800, C530S300000, C530S324000, C530S325000, C530S326000, C530S327000, C530S334000, C530S344000, C435S069100
Reexamination Certificate
active
06911425
ABSTRACT:
Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in matrix extracellular phosphoglycoprotein. The sequences may be formulated for injection or dispersed in toothpaste or a mouthwash or gum patch and administered to enhance bone/tooth growth and/or reduce excessive urinary phosphate loss from the body.
REFERENCES:
patent: 5849865 (1998-12-01), Cheng et al.
patent: 6146655 (2000-11-01), Ruben
patent: 6673900 (2004-01-01), Rowe
patent: WO 95/14714 (1995-06-01), None
patent: WO 99/08730 (1999-02-01), None
patent: WO 99/48909 (1999-02-01), None
patent: WO 99/48909 (1999-09-01), None
patent: WO 99/60017 (1999-11-01), None
patent: WO 02/05836 (2002-01-01), None
Chappard et al., (1995) “Effects of tiludronate on bone loss in paraplegic patients.”Journal of Bone and Mineral Research, 10(1):112-118.
Fratzl et al., (1994) “Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle x-ray-scattering study.”Journal of Bone and Mineral Research, 9(10):1541-1549.
Gennari et al., (1994) “Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.”Drug Saf., 11(3):179-95.
Gronowicz et al., (1994) “Synthetic peptide containing Arg-Gly-Asp inhibits bone formation and resorption in a mineralizing organ culture system of fetal rat parietal bones.”Journal of Bone and Mineral Research, 9(2):193-201.
Hilfiker, (1998) “Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine.”Proc. Natl. Acad. Sci. USA, 95(24):14564-14569.
Lufkin et al., (1994) “Pamidronate: an unrecognized problem in gastrointestinal tolerability.”Osteoporos. Int., 4(6):320-322.
Mundy et al., (1999) “Stimulation of bone formation in vitro and in rodents by statins.”Science, 286:1946-1949.
Rowe et al., (2000) “MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.”Genomics, 67:54-68.
Schneider et al., (1995) “Does HRT modify risk of gynecological cancers?”Int. J. Fertil. Menopausal Study, 40(1):40-53.
Traianedes et al., (1998) “5-Lipoxygenase metabolites inhibit bone formation in vitro.”Endocrinology, 139:3178-3184.
Bairoch et al. (1990) “EF-hand motifs in inositol phospholipid-specific phospholipase C. ”FEBS, vol. 269(2):454-456.
Chauvaux et al. (1990) “Calcium-binding affinity and calcium-enhanced activity of Clostridium thermocellum endoglucanase D. ”Biochem. J., vol. 265:261-265.
Davis (1990) “The many Faces of Epidermal Growth Factor Repeats. ”The New Biologist, vol. 2(5):410-419.
Economou et al. (1990) “The Rhizobium nodulation gene nodO encodes a Ca2+-binding protein that is exported without N-terminal cleavage and is homologous to haemolysin and related proteins.”The EMBO Journal, vol. 9(2):349-354.
Kawasaki et al. (1995) “Calcium-Binding Proteins 1: EF-hands. ”Protein Profile, vol. 2(4):305-356.
Moncrief et al. (1990) “Evolution of EF-Hand Calcium-Modulated Proteins. I. Relationships Based on Amino Acid Sequences. ”J. Mol. Evol., vol. 30:522-562.
Schafer et al. (1995) “Isolation of a YAC Clone Covering a Cluster of Nine S100 Genes on Human Chromosome 1q21: Rationale for a New Nomenclature of the S100 Calcium-Binding Protein Family. ”Genomics, vol. 25:638-643.
Springer et al. (2000) “A Novel Ca2+Binding β Hairpin Loop Better Resembles Integrin Sequence Motifs than the EF Hand. ”Cell, vol. 102:275-377.
Ferris D. M. et al., “RGD-coated titanium implants stimulate increased bone formation in vivo” Biomaterials, Vo. 20, No. 23-24, Dec. 1999. pp. 2323-2331.
Hayashibara T. et al., “A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo” Journal of Bone and Mineral Research, New York, NY., US, vol. 19, No. 3, Mar. 2004, pp. 455-462.
Lopez-Moratalla et al., “A common structural motif in Immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells” Biochimica et Biophysics Acta, vol. 1317, No. 3, 1996, pp. 183-191.
Blacher Russell Wayne
Kumagai Yoshinari
Yoneda Toshiyuki
Acologix, Inc.
Bozicevic Karl
Bozicevic Field & Francis LLP
Kam Chih-Min
Weber Jon
LandOfFree
Integrin binding motif containing peptides and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin binding motif containing peptides and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin binding motif containing peptides and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3503352